Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
- Conditions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT05527964
- Locations
- 🇨🇿
Investigational Site: Bulovka University Hospital, Prague, Czechia
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT05526521
- Locations
- 🇺🇸
Washington University School of Medicine- Site Number : 8400004, Saint Louis, Missouri, United States
🇺🇸Childrens Hospital Medical Center of Akron- Site Number : 8400020, Akron, Ohio, United States
🇺🇸Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001, Cincinnati, Ohio, United States
Real World Study on the Use of Cemiplimab in Adult Patients in UK
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 110
- Registration Number
- NCT05493826
- Locations
- 🇬🇧
Sanofi-Aventis UK, Reading, Berkshire, United Kingdom
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1310
- Registration Number
- NCT05492578
- Locations
- 🇺🇸
First OC Dermatology- Site Number : 8401025, Fountain Valley, California, United States
🇺🇸Sunwise Clinical Research- Site Number : 8401022, Lafayette, California, United States
🇺🇸Clinical Science Institute- Site Number : 8401028, Santa Monica, California, United States
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT05468320
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center Site Number : 8400005, Boston, Massachusetts, United States
🇺🇸University of Minnesota Site Number : 8400013, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center Site Number : 8400022, Durham, North Carolina, United States
A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT05453942
- Locations
- 🇩🇪
Investigational Site Number :2760001, Berlin, Germany
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT05450562
- Locations
- 🇺🇸
USCA Norris Comprehensive Cancer Center Site Number : 8400004, Los Angeles, California, United States
🇨🇦Investigational Site Number : 1240002, Toronto, Ontario, Canada
🇨🇳Investigational Site Number : 1560001, Shanghai, China
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
- Conditions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT05442645
- Locations
- 🇨🇳
Investigational site-National Taiwan University Hospital, Taipei, Taiwan, China
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT05429762
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center Site Number : 8400002, Dallas, Texas, United States
🇪🇸Investigational Site Number : 7240002, Barcelona, Catalunya [Cataluña], Spain
🇹🇷Investigational Site Number : 7920001, Ankara, Turkey
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 446
- Registration Number
- NCT05421598
- Locations
- 🇨🇦
Investigational Site Number : 1240006, Brampton, Ontario, Canada
🇺🇸Pines Care Research Center LLC Site Number : 8400028, Pembroke Pines, Florida, United States
🇺🇸South Bend Clinic Site Number : 8400033, South Bend, Indiana, United States